KORU Medical Systems vs Nephros
KRMD and NEPH side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRMD and NEPH compare
KORU Medical Systems is the larger company, worth 5.4 times as much as Nephros ($180M against $33.3M).
Nephros grew revenue faster over the last twelve months (20.4% versus 18.4% for KORU Medical Systems).
Nephros keeps more of each dollar of sales as profit, with a net margin of 8.9% compared with −1.8% at KORU Medical Systems.
Nephros scores higher on the StockData Score (13 against 12 for KORU Medical Systems), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRMD | NEPH |
|---|---|---|
| Size and price | ||
| Market cap | $180M | $33.3M |
| Share price | $3.89 | $3.07 |
| Change, 1 year | −0.77% | −28.4% |
| Change, 5 years | 14.4% | −58.6% |
| Beta (5Y) | 1.00 | 0.58 |
| Employees | 73 | 36 |
| StockData Score | ||
| Total score | 12 | 13 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 17.1× |
| P/S | 3.9× | 1.5× (better) |
| P/B | 9.3× | – |
| EV/EBITDA | 866× | 14.8× (better) |
| FCF yield | −0.22% | – |
| Fair value | – | $4.25 |
| Margin of safety | – | 27.7% |
| Growth | ||
| Revenue growth (TTM) | 18.4% | 20.4% (better) |
| Revenue growth, 5Y average | 11.2% | 17.0% (better) |
| Net income growth (TTM) | – | 29.0% |
| EPS growth (TTM) | – | 38.5% |
| Profitability | ||
| Gross margin | 63.6% (better) | 60.5% |
| Operating margin | −1.3% | 8.5% (better) |
| Net margin | −1.8% | 8.9% (better) |
| FCF margin | −0.84% | – |
| Return on equity | −4.6% | – |
| Return on invested capital | −4.7% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 2.97 | 5.50 (better) |
| Altman Z-score | 12.00 (better) | −3.01 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 44.5% | 48.9% |
| Held by insiders | 17.6% | 9.2% |
| Insider net buying, 12 months | $1.6M | – |
| Short interest, % of float | 2.3% | 0.12% |
Go deeper
- KRMD stock overview
- KRMD income statement
- KRMD valuation and score
- NEPH stock overview
- NEPH income statement
- NEPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.